What are biosimilars?
Biological medicines (so-called biologics) are innovative medicines that can change the lives of millions of patients with diseases that are severely incapacitating or can lead to death.
Depending on the approach of the various health authorities, biosimilars can contribute to facilitating the access of patients, doctors and cost-bearers to medicines.
Biosimilars lead to the same result: a biological original preparation and a biosimilar are like a key and its copy made by a locksmith. They may look minimally different, but the result is the same: they both fit into the same lock and open the door.
History of biosimilars
In Europe, the first biosimilar was authorised by the European Medicines Agency (EMA) in the year 2006. EMA is responsible for authorisations of biopharmaceuticals and biosimilars in all the countries of the European Union. In Switzerland, it is swissmedic, Agency for Therapeutic Products and Swiss authorisation authority for medicines, that is responsible for authorising biosimilars, as in the case of generics.
«The molecule of the original product and of the biosimilar must be identical structurally and regarding their detailed complexities to the extent that there is no difference in their effect.»
Prof. Dr. Theodor Dingermann, Institute for Pharmaceutical Biology, Goethe University Frankfurt a. M.